Yin X - Search Results

1

Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.

Zhang Y, Yu M, Jing Y, Cheng J, Zhang C, Cheng L, Lu H, Cai MC, Wu J, Wang W, Lou W, Qiu L, Tan L, Lu H, Yin X, Zhuang G, Di W. Zhang Y, et al. Among authors: yin x. Br J Cancer. 2021 Jan;124(2):414-424. doi: 10.1038/s41416-020-01123-w. Epub 2020 Oct 22. Br J Cancer. 2021. PMID: 33087896 Free PMC article.

2

Regulation of LC3-dependent protective autophagy in ovarian cancer cells by protein phosphatase 2A.

Yin X, Zhang N, Di W. Yin X, et al. Int J Gynecol Cancer. 2013 May;23(4):630-41. doi: 10.1097/IGC.0b013e3182892cee. Int J Gynecol Cancer. 2013. PMID: 23518861

3

Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.

Wang Y, Liu P, Duan Y, Yin X, Wang Q, Liu X, Wang X, Zhou J, Wang W, Qiu L, Di W. Wang Y, et al. Among authors: yin x. Biomaterials. 2014 Jan;35(3):983-92. doi: 10.1016/j.biomaterials.2013.09.062. Epub 2013 Oct 28. Biomaterials. 2014. PMID: 24176193

4

Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies.

Liu T, Chen L, Sun X, Wang Y, Li S, Yin X, Wang X, Ding C, Li H, Di W. Liu T, et al. Among authors: yin x. Tumour Biol. 2014 Mar;35(3):2427-36. doi: 10.1007/s13277-013-1322-x. Epub 2013 Nov 7. Tumour Biol. 2014. PMID: 24197980

5

FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer.

Zhou J, Wang Y, Wang Y, Yin X, He Y, Chen L, Wang W, Liu T, Di W. Zhou J, et al. Among authors: yin x. PLoS One. 2014 May 13;9(5):e96989. doi: 10.1371/journal.pone.0096989. eCollection 2014. PLoS One. 2014. PMID: 24824601 Free PMC article.

6

A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.

Yin X, Wang X, Shen B, Jing Y, Li Q, Cai MC, Gu Z, Yang Q, Zhang Z, Liu J, Li H, Di W, Zhuang G. Yin X, et al. Sci Rep. 2016 Aug 8;6:31079. doi: 10.1038/srep31079. Sci Rep. 2016. PMID: 27498762 Free PMC article.

7

Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.

Zhang Z, Peng H, Wang X, Yin X, Ma P, Jing Y, Cai MC, Liu J, Zhang M, Zhang S, Shi K, Gao WQ, Di W, Zhuang G. Zhang Z, et al. Among authors: yin x. Mol Cancer Ther. 2017 Sep;16(9):1739-1750. doi: 10.1158/1535-7163.MCT-17-0078. Epub 2017 Jun 1. Mol Cancer Ther. 2017. PMID: 28572168

8

Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer.

Yin X, Jing Y, Cai MC, Ma P, Zhang Y, Xu C, Zhang M, Di W, Zhuang G. Yin X, et al. Cancer Res. 2017 Dec 1;77(23):6551-6561. doi: 10.1158/0008-5472.CAN-17-1461. Epub 2017 Sep 28. Cancer Res. 2017. PMID: 28972072

9

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors.

Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, Wang X, Di W, Zhuang G. Zhang S, et al. Among authors: yin x. Nat Commun. 2018 Jan 15;9(1):215. doi: 10.1038/s41467-017-02693-9. Nat Commun. 2018. PMID: 29335437 Free PMC article.

10

Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR/ERK pathway Activation for Ovarian Cancer Therapy.

Cui X, Sun Y, Shen M, Song K, Yin X, Di W, Duan Y. Cui X, et al. Among authors: yin x. ACS Appl Mater Interfaces. 2018 Mar 7;10(9):7821-7831. doi: 10.1021/acsami.7b19183. Epub 2018 Feb 20. ACS Appl Mater Interfaces. 2018. PMID: 29411964

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,884 results

Search Page

Filters